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ORIGINAL ARTICLE
Cumulative effects of heat exposure and storage
conditions of Oxytocin-in-Uniject in rural Ghana:
implications for scale up
Luke C Mullany,a Sam Newton,b Samuel Afari-Asiedu,b Edward Adiibokah,b Charlotte T Agyemang,b
Patience Cofie,c Steve Brooke,c Seth Owusu-Agyei,b Cynthia K Stantona
Oxytocin-in-Uniject devices could be stored 30 to 40 days without refrigeration under typical field
conditions, with wastage levels below 10%, based on simulation studies.
ABSTRACT
Objective: Postpartum hemorrhage can be reduced substantially in home deliveries attended by community-based
workers by using Oxytocin-in-Uniject (OIU) devices affixed with temperature-time indicators. We characterized the
distribution of time to discard of these devices when stored under normal field conditions in Ghana.
Methods: Two drug storage simulation studies were conducted in rural Ghana in 2011 and 2012. Devices were
transported under refrigeration from manufacture (Argentina) to storage at the study site. Twenty-three field workers
each stored at home (unrefrigerated) 25 OIU devices and monitored them daily to record: (1) time to transition from
usable to unusable, and (2) continuous digital ambient temperature to determine heat exposure over the simulation
period. Time to discard was estimated and compared with mean kinetic temperature exposure of the devices during the
shipment and storage phases and with characteristics of the storage locations using Weibull regression models. We used
the time to discard distributions in a Monte Carlo simulation to estimate wastage rates in a hypothetical program setting.
Results: Time for shipment and transfer to long-term refrigerated storage and mean kinetic temperature during the
shipment phase was 8.6 days/10.3 C˚ and 13.4 days/12.1 C˚, for the first and second simulation studies, respectively.
Median (range) time to discard when stored under field conditions (unrefrigerated) was 43 (6 to 59) days and
33 (14 to 50) days, respectively. Mean time to discard was 10.0 days shorter in the second simulation, during which
mean kinetic temperature exposure was 3.9 C˚ higher. Simulating a monthly distribution system and assuming typical
usage, predicted wastage of product was less than 10%.
Conclusion: The time to discard of devices was highly sensitive to small changes in temperature exposure. Under field
conditions typical in rural Ghana, OIU packages will have a half-life of approximately 30 to 40 days based on the
temperature monitor used during the study. Program managers will need to carefully consider variations in both
ambient temperature and rate of use to allocate the appropriate supply level that will maximize coverage and minimize
stock loss.
INTRODUCTION
O xytocin has been included on the World HealthOrganization (WHO) Model List of Essential
Medicines since it was first published in 1977,1 and it
is the drug of choice to prevent and treat post-
partum hemorrhage—the leading cause of maternal
death globally.2 There is considerable international
commitment to expanding access to this drug, as
reflected in recent recommendations from the UN
Commission on Life-Saving Commodities for Women’s
and Children’s Health. These recommendations include
developing effective global mechanisms for pooled
procurement and aggregated demand; supporting at
least 3 manufacturers to develop and market high-
quality, competitively priced oxytocin; and standardizing
national regulatory processes for oxytocin registration.3
An important constraint to expanding access is that
oxytocin is not heat stable, a key consideration in
peripheral settings in low-income countries where
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consistent and reliable cold-storage capability is
often lacking.4 This factor discourages health
planners from procuring oxytocin for peripheral
sites and could lead to waste and/or discarding of
potentially usable oxytocin due to concerns about
loss of potency. On the other hand, lack of heat
stability can lead to sale and use of poor-quality
oxytocin; for example, 74% of oxytocin samples
purchased at private pharmacies in Ghana were
outside manufacturer specification for active
pharmaceutical ingredient (API).5
Current International Pharmacopoeia guidelines
recommend storing oxytocin at 2 C˚ to 8 C˚ and
protecting it from light exposure, but the drug
can withstand moderate heat exposure.6 A
simulated temperature exposure study demon-
strated that when exposed to either low (4 C˚ to
8 C˚) or high (30 C˚) temperature continuously for
12 months, oxytocin retained 100% and 86% of
its API, respectively, and was not affected by
light exposure.4 The authors recommended that
all oxytocics be refrigerated to the extent possible
but that temporary storage up to 30 C˚ for
3 months was acceptable.
One possible strategy for extending access to
oxytocin to the peripheral health system would
be to store the drug under cold-chain conditions
at regional drug depots and health facilities with
reliable refrigeration (as used for vaccines), and
then for community-based providers to maintain
a smaller temporary supply outside the cold
chain, only accessing the refrigerated stock
periodically for resupply. For this approach to
be successful, the community-based providers
would need to know the point at which an
individual ampoule or injection device for oxyto-
cin should be discarded. This would depend on
cumulative exposure to heat, which would be
expected to vary under different field conditions.
Temperature-time indicators (TTIs) that change
color in response to cumulative heat exposure
provide a solution for this issue. The TTI is a
simple label depicting a square enclosed in a
circle (Figure 1); as the TTI (and therefore the
drug) is cumulatively exposed to heat, the inner
square begins to darken (a signal to prioritize use
of this drug first), and then reaches the same
color (or darker) than the outer circle, signaling
that the drug should be discarded.
We recently completed a cluster-randomized
trial of the effect of prophylactic use of Oxytocin-
in-Uniject (OIU) on postpartum hemorrhage
among home deliveries, which found that OIU
reduced postpartum hemorrhage by half in home
deliveries in Ghana.7,8 OIU is a prefilled, sterile,
non-reusable injection device with a single, 10 IU
dose of oxytocin. In that trial, we conducted a
sub-activity to systematically assess the duration
that oxytocin can be stored outside the cold
chain based on use of a TTI that had been applied
to the foil envelopes containing the OIU devices.
Specifically, we aimed to estimate the overall
distribution and median time to reaching the
discard point when oxytocin is removed from the
cold chain and stored under realistic field
conditions in rural Ghana.
The specific TTI used in this study, and that
has been used previously for oxytocin, was
designed to reach the discard point at the
equivalent of 17.2 days at 40 C˚, 72.5 days at
30 C˚, or 154 days at 25 C˚. The choice of this
particular TTI is conservative, as oxytocin
exposed to these heat equivalents could actually
remain within API specifications for longer time
periods. Because the TTI was designed for
monitoring vaccine vials, it does not function
correctly when exposed to ultraviolet light and
thus, if used to monitor oxytocin, requires
storage in darkness.
METHODS
This study was a sub-activity of a larger cluster-
randomized trial of the impact of OIU on
postpartum hemorrhage among women deliver-
ing at home in the Brong-Ahafo region of Ghana,
the design7 and results8 of which have been
published previously. In the randomized trial,
FIGURE 1. Visual Changes to the Temperature-Time Indicator
Resulting From Cumulative Heat Exposure
Oxytocin is the
drug of choice to
prevent and treat
postpartum
hemorrhage, but
access has been
constrained
because it needs
to be refrigerated.
Temperature-time
indicators change
color in response
to cumulative
heat exposure,
providing a way
for health workers
to monitor
usability of
oxytocin kept
outside the cold
chain.
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OIU devices (with TTI) were distributed to
community health officers (CHOs) on a regular
basis guaranteeing that they would have a
sufficient supply when called (by mothers/family
members) at the time of labor and delivery. The
CHOs maintained their supply of OIU without
refrigeration in their assigned Community-based
Health Planning and Services (CHPS) com-
pound. During trial implementation, the CHOs
used only those devices for which the TTI
indicated that the drug had not yet reached the
discard point.
Overview of the Simulation Study
We were interested in systematically characteriz-
ing the distribution of time to which the TTI
reached the discard point. During a pre-
simulation phase between 2010 and 2011, we
monitored the state of the OIU devices and the
temperature conditions during storage from the
time between manufacture and shipping to our
storage facility at the Kintampo Health Research
Centre (KHRC) in Kintampo, Ghana, and during
storage at that site. We then conducted a
simulated storage activity between 2011 and
2012 by asking field workers to store a quantity
of devices in their homes while monitoring once
daily the status of the TTI. Ambient temperature
was monitored using a LogTag device, a battery-
operated, digital ambient temperature recorder.
The simulation exercise was conducted twice
using different shipments of OIU devices during
2 different calendar periods, representing season-
al variation in rural Ghana. We also collected
some basic information regarding the character-
istics of field workers’ homes and how they
stored the devices out of refrigeration.
Pre-Simulation: Temperature Monitoring
From Manufacture to Arrival at KHRC
Prior to shipment from Biol, the Argentina-based
manufacturer of the OIU used in this study,
LogTag devices were placed in the containers used
to transport the OIU in order to monitor the
temperature to which the OIU devices were
exposed during shipment from manufacturing site
to storage at the KHRC. Two such pre-simulation
studies were conducted on separate batches of OIU
devices. Devices used in the first pre-simulation
were shipped in August 2010, while the second set
of devices was shipped in November 2011. In each
shipment, there were 2 separate containers; within
each was packed a separate LogTag, and these
devices were synchronized to record at the same
time points and with equal recording interval
(every 30 and 15 minutes for the 2010 and 2011
shipments, respectively). For both batches, OIU
devices were manufactured and stored at Biol, air
transported under refrigeration from Buenos
Aires, Argentina, to Johannesburg, South Africa,
to Accra, Ghana. Upon arrival in Ghana, the
containers remained at the airport (a non-climate-
controlled environment) through customs proc-
essing, before being transported by road to the
KHRC in Kintampo (a distance of about 450 km),
and being returned to refrigeration upon arrival at
the center. The LogTag collected data continuously
from preparation of the shipment from Biol until
placement of the OIU devices in controlled
refrigeration at KHRC, where they were stored at
2 C˚ to 8˚ C until received by field workers for the
simulation exercise.
Simulated Field-Based Storage Exercise
Starting in July 2011, and again in February
2012, we exposed packages of OIU devices to
continuous ambient temperatures in the com-
munity. To avoid wastage, the OIU device itself
was removed from its package, because we were
interested only in monitoring the time for the TTI
that was adhered to the package to reach the
point of discard.
We chose 23 field workers to conduct this
simulation and collect the monitoring measure-
ments. All field workers were KHRC workers
actively engaged in the parent randomized trial
within which this activity was nested. We
provided each field worker with 25 packages
stapled to a piece of cardboard for easy viewing.
In order to prevent direct exposure to light, the
board was folded and placed in a small backpack
during storage in the field worker’s house. Each
OIU package was pre-labeled with a unique
identifying number.
Workers used a calendar data collection form
into which he/she recorded the status of the TTI
on a daily basis with 1 of 3 values:
N ‘‘1’’ (inner square lighter than outer circle)
N ‘‘2’’ (inner square same color as outer circle)
N ‘‘3’’ (inner square darker than outer circle)
A value of ‘‘2’’ corresponds to the discard
point of interest in this study. In addition to the
25 devices, also included in each backpack was a
LogTag device, set to record the temperature
within the storage container at regular intervals.
The temperature was recorded in degrees Celsius
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every 10 minutes and every 23 minutes in the
first and second rounds, respectively. Field
workers checked the status of their packages
each morning and continued doing so until the
TTI for all 25 packages on their board had
reached the discard point.
Characterization of Storage Locations
Basic information about each field worker’s
storage location was collected. These data
included the district (Kintampo North vs.
South); GPS waypoints; the storage location
within the household; exposure of the backpack
(in which the OIU packages were stored) to
direct sunlight; construction materials used for
roof, ceiling, wall, and floor; presence of fan; and
whether the field worker cooked in the same
room in which the devices were stored.
Sample Size
We calculated the number of devices required to
estimate with 95% confidence the median time to
discard within 1 week (+/2 7 days). To do so, we
assumed that the probability of discard increases
with time, and thus anticipated modeling the
time to discard using a Weibull distribution;
without prior knowledge we assumed the mean
time would be 180 days with a shape parameter
of 3. For sample sizes ranging from 100 to 1,000,
we simulated 10,000 datasets distributed as
Weibull with these parameters, and we estimated
the proportion of datasets resulting in median
discard times within 7 days of the median
parameter; this proportion reached 95% when
the sample size was 580. Therefore, we distrib-
uted 25 OIU packages to each of 23 field workers
for a total of 575 OIU packages.
Analysis
The pre-simulation data (data on storage and
handling of the OIU devices from manufacture to
shipping to the storage facility at KHRC) were
analyzed as follows: For each time point during
transport, the exposure temperature was defined
as the average temperature recorded by the
2 LogTag devices at that time point. The curve of
temperature exposure for the first and second
shipments was plotted over the time of shipment.
In order to visualize and compare across the
2 shipments, the x-axis (in units of days) was
standardized such that elapsed time was relative to
the moment of shipment from Biol. Mean kinetic
temperature for each shipment was calculated
over the period of shipment using the batch-
specific interval temperature measurements.
For the simulation exercise, the date at which
the field worker received the test packages was
defined as time 0 (T0). For each package, the
time of discard, Tf, was defined as the date that
the field worker first recorded a switch from ‘‘1’’
to ‘‘2’’ (that is, when the inner square reached
the same color as the outer circle), and the
difference between T0 and Tf indicated the time
to discard. The Kaplan-Meier estimate of the
survival (discard) function was constructed, and
the median and 95% confidence interval (CI)
were estimated. Individual scatter plots of
ambient temperature exposure across the time
period of the simulation exercise were con-
structed. For each package, a measure of ambient
temperature exposure was estimated by calculat-
ing the mean kinetic temperature from individ-
ual daily estimates of minimum/maximum
temperature. To determine the effect of ambient
temperature exposure and to examine other
variables such as shipment (first vs. second),
district (Kintampo North vs. South), and char-
acteristics of the storage location, we estimated
hazards ratios using a Weibull survival regression
model and accounted for possible correlation
within storage location using the Huber-White
sandwich estimator. Mann-Whitney tests were
used to compare the distribution of summary
measures (mean, standard deviation, maximum,
minimum) of temperatures to which each of the
23 groups of 25 devices were exposed during
Phase 1 and Phase 2 with selected characteristics
of the storage location, including roof and wall
materials, presence of ceiling or a fan in the
room, and whether the storage room was also
used for cooking. Those found significant were
then examined for their association with time to
discard in Weibull regression models. We con-
ducted a Monte Carlo simulation study using the
estimated distribution of time to discard, in order
to estimate the wastage that might occur in a
hypothetical scaled-up program with monthly
distribution and provision of a 10% buffer
(excess supply beyond predicted actual use). All
analyses were done with STATA 12.1.
RESULTS
Pre-Simulation Studies
For each of the 2 batches included in the pre-
simulation study, the transportation period con-
sisted of 6 distinct stages:
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FIGURE 2. Average Ambient Temperature Exposure During Shipment Period, by Batch
Abbreviation: KHRC, Kintampo Health Research Centre.
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1. En route from manufacturer to Buenos Aires
2. En route to South Africa
3. En route to Ghana
4. Customs and storage in Accra, Ghana
5. En route to KHRC
6. Storage in KHRC
The pattern of fluctuation in temperature to
which the devices were exposed during these
6 transportation stages was similar between batch
1 (Figure 2a) and batch 2 (Figure 2b), but overall
exposure was higher in the second batch
(Figure 2c), mainly due to higher temperature
during the road transport stage. Mean kinetic
temperature exposure prior to reaching long-term
storage in the KHRC refrigerators was 10.3 C˚ and
12.1 C˚ in batch 1 and batch 2, respectively. Total
duration from shipment to storage in KHRC for
the first and second pre-simulation studies was
8.6 and 13.4 days, respectively.
Simulation Study
The first simulation study started on July 25,
2011. Among 23 field workers initially provided
with 25 OIU packages each, TTI status data were
available for 550 of the 575 packages; informa-
tion for all 25 packages for 1 field worker was
missing for 1 month, during which all the
indicators reached the discard point, thus the
discard time could not be determined.
Among the 550 packages with analyzable
data, the durations at which the TTI indicators
reached the discard point ranged from 6 to
59 days, and the median time was 43 days
(95% CI543–45) (Figure 3). At 30 days, a
common interval for community-based resupply
of materials, 16% (88/550) of the packages had
reached the discard point. Mean kinetic tem-
peratures recorded across the 23 field workers’
storage sites during the first simulation ranged
from 25.1 C˚ to 28.5 C˚.
The second simulation study used OIU
packages from the second shipment batch and
was started on February 1, 2012. Among 23 field
workers provided with 25 OIU packages each,
information from this simulation exercise was
available for all 575 packages. The durations at
which the TTI reached the discard state during
the second simulation study ranged from 14 to
50 days, and the median time was 33 days
(95% CI531–33). At 30 days, 34% (196/575) of
packages reached the discard state. Mean kinetic
temperatures recorded across the 23 field work-
ers’ storage sites during the second simulation
ranged from 27.6 C˚ to 33.0 C˚.
The mean time to reaching discard was
10.0 days (95% CI54.4–15.7) shorter in the
second study than in the first, and the hazard
ratio of reaching discard was approximately
3.64 times higher (95% CI52.03–6.52). This
was, however, nearly fully explained by the
difference in ambient temperature exposure
between the 2 simulation periods (Figure 4).
The average maximum daily temperature across
all OIU packages was approximately 3.9 C˚
(95% CI53.6–4.3) higher during the second
study period (32.8 C˚) compared with the first
study period (28.9 C˚). Each degree increase in
mean kinetic temperature increased the hazard
of discard by 1.60 (95% CI51.28–2.00).
Individual OIU packages were exposed to a
wide range of temperatures, and, in some cases,
there was substantial variation in exposure
temperatures by field worker, illustrated with
scatter plots of the individual LogTag measure-
ments collected by each of the 23 workers in the
first (Figure 5a) and second studies (Figure 5b).
Differences in temperatures were also seen by
district, with the northern part of the study area
FIGURE 3. Proportion of Packages With TTI Status of Usable
Over Time, by Simulation Exercise
Abbreviation: TTI, temperature-time indicator.
Mean kinetic
temperature/time
exposure between
shipment of the
devices and
storage at the
central facility was
10˚ C–12˚ C /
9–13 days.
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having consistently higher average exposure
temperature than the southern portion.
All 23 workers reported that they were able to
store their packages out of direct sunlight within
their homes. None of the household character-
istics examined were associated with mean,
maximum, or minimum temperatures measured.
However, variation in temperature was signifi-
cantly higher among the 13 workers reporting
that they had no ceiling (compared with
10 others reporting either a plywood or mat
ceiling). Concurrently, many of these same
13 workers indicated that they felt their room
became very hot because they did not have a
ceiling. The hazard of discard was approximately
1.60 times higher (95% CI50.98–2.64) for
devices stored in homes without a ceiling than
in those with a ceiling.
In our Monte Carlo estimation, frequency of
supply was set at 30 days (monthly distribution),
and quantity of supply was sufficient to cover
expected usage plus a 10% buffer. Using the time
to discard distributions of the first and second
field simulation exercises, the expected wastage
rate was 3.5% and 8.8%, respectively.
DISCUSSION
The results of these 2 simulation activities indicate
that in rural Ghana, the median time between
distribution to field workers and transition to a
non-usable state for Oxytocin-in-Uniject (based
on the TTI in current use) is on the order of
30 to 40 days (4 to 6 weeks) and is highly
dependent on ambient temperature. Using a
commonly used monthly resupply schedule, the
number of devices discarded would be very low if
the true discard time followed a distribution
similar to that observed in this study, because a
substantial proportion of devices would be used
(rather than simply stored) before reaching
discard. It is important to note that our simulation
study did not include cold-chain storage at the
final stage (that is, with the field workers), as is
typical of many low-resource settings. However,
we acknowledge that the cold chain was main-
tained at our central site, prior to distribution to
the field workers, which in some instances may
not be achieved in program settings.
The number that would be lost to heat
exposure is a complex interaction between the
FIGURE 4. Daily Maximum and Minimum Temperature, by Day, for First and Second Simulation Exercises
Median time to
discard was
43 days and
33 days, in the
first and second
simulation studies,
respectively.
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FIGURE 5. Scatter Plots of Temperature Readings by LogTag Device
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rate of use, the excess supply provided (the
proportion provided to the worker that is beyond
the expected number that will be used), and the
specific distributional characteristics of the time
to discard. Our data from the first and second
simulation exercises indicate that 16% and
34% of packages, respectively, reached the dis-
card point within 30 days when not being used
(that is, they were stored only). It is essential to
note, however, that the actual wastage would be
substantially less than this, because in an actual
program setting, the devices would be used, not
simply stored. When this usage was taken into
account in our Monte Carlo estimation, we found
predicted wastage rates to be substantially lower
than 10%
Limitations and Strengths
There are a number of limitations to this study.
The first is that we characterized only the
distribution of time to discard the packages,
based on cumulative exposure to heat of the TTIs.
While this is a proxy for heat degradation of
oxytocin that would, under programmatic imple-
mentation, be stored within these packages, an
endpoint of greater interest is the API remaining
at various time points over this time range. It is
unlikely that the actual API levels of oxytocin
stored under similar conditions would follow
both the shape and scale parameters of curves for
the device packages shown in Figure 3. This is
because our empiric estimates of the distribution
of time to discard indicates that 100% ‘‘failure’’
occurs on the order of 50 to 60 days, while assays
of oxytocin API have generally demonstrated
much slower attrition of API under similar
temperatures.4 Furthermore, the quantitative
relationship between deviations from 90% to
110% API, the manufacturer’s range of accepta-
ble API, and actual clinical effectiveness of
oxytocin is not well understood. For example, a
Cochrane Review of the effects on postpartum
bleeding of prophylactic oxytocin administered
during the third stage of labor included clinical
trials in which the dosage of oxytocin varied
from 3 to 10 IU, and the mode of delivery
included intramuscular injection and intrave-
nous administration.9 Thus, it is possible that
many of the devices that would need to be
discarded as ‘‘non-usable’’ when following the
TTI in current use might contain oxytocin that is
still within manufacturer specification. Further
research is needed to better quantify the optimal
level of oxytocin required to produce a clinically
sufficient response.
Another limitation is that we did not have
sufficient overlap in ambient temperature expo-
sure between phase 1 and phase 2. That is, the
mean kinetic temperature to which packages in
phases 1 and 2 were exposed rarely overlapped,
and thus phase and ambient temperature were
too highly correlated for us to determine the
impact of the higher mean kinetic tempera-
ture exposure during shipment of the phase
2 containers.
This simulation study, however, did use
LogTags to document daily variation in tempera-
ture exposures from manufacturer to storage in
the field under realistic conditions in Ghana and
to show how sensitive the time to discard point
was to relatively small absolute changes in
ambient temperature. Furthermore, our study
included a large number of units (N5550 to 575)
examined during 2 different seasons, allowing us
to accurately characterize the distributional
parameters of the time to discard. By distributing
these devices across a set of 23 field workers and
collecting characteristics of the storage location,
we were also able to further understand the
degree to which storage conditions (such as
common building construction techniques)
influence this distribution of time to discard.
CONCLUSION
With careful handling of the drug during
transport from manufacture to the main storage
facility, and careful planning around the appro-
priate levels of provision to field workers, given
known information about rate of use (i.e., the
number of units used per day or month),
program managers could effectively resupply
field workers without refrigeration access with
an appropriate level (based on a known usage
rate) of Oxytocin-in-Uniject devices (or ampoules
of oxytocin) on a monthly basis. Such a schedule
would result in high levels of coverage with low
overall overage or wastage percentages and
would fit with common current resupply sched-
ules for other materials and meeting/supervision
schedules.
The TTI used in this study is very conservative
with time to discard temperature indicators set at
30 C˚ to 35˚ C; even lower levels of wastage or more
flexible scheduling and resupply schemes could be
implemented with a TTI designed to reflect
oxytocin stability more closely. Manufacturers
At 30 days,
wastage levels
ranged from
16%–34% in the
simulations;
actual wastage
would be less
because field
workers would
use some of the
devices.
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could play a role in accelerating programmatic
implementation in low-resource settings by devel-
oping such a TTI with greater specificity for
oxytocin, by improving flexibility in packaging
such that TTIs could be affixed to either OIU
packages or oxytocin vials (which are more widely
available and cost less), and by further elucidating
the relationship between temperature exposure
and API under various conditions. Oxytocin
remains the drug of choice for prevention of
postpartum hemorrhage, and OIU has been
demonstrated to reduce postpartum hemorrhage
by half in home deliveries in Ghana.8 The data
from this simulation study provide some guidance
to program managers as to how this effective
intervention might be rolled out at scale and how
oxytocin could be used at peripheral health
facilities without cold-chain capacity.
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